HOME >> MEDICINE >> NEWS
Ireland Cancer Center researcher lays out benefits of aspirin to prevent colon cancer

A colon cancer researcher at the Ireland Cancer Center of University Hospitals Case Medical Center (UHCMC) has laid out the roadmap for how medical science should employ aspirin and new aspirin-like drugs for use in preventing colon cancer in certain high-risk individuals.

In today's New England Journal of Medicine, Sanford Markowitz, MD, PhD, writes an editorial accompanying research from Dr. Charles Fuchs' team at Harvard Medical School that lays out the hypothesized mechanism by which the use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), also called COX-2 inhibitors, act to decrease the risk of developing colon cancer.

"The compelling evidence that chronic use of aspirin or certain NSAIDS can substantially lower the risk of colon cancer has important implications, especially because colon cancer is the second leading cause of cancer death," writes Dr. Markowitz, the Francis Wragg Ingalls Professor of Cancer Genetics at UHCMC and Case Western Reserve University School of Medicine.

In the Journal article, the Harvard researchers' findings demonstrated that two-thirds of colon cancers have high levels of expression of the COX-2 enzyme, which is blocked by aspirin. Individuals who regularly used aspirin over a course of several years demonstrated a 36% decrease in the risk of developing one of these high COX-2 expressing colon cancers. These results again demonstrated that drugs that block COX-2 can decrease the risk of colon cancer, and demonstrated that such drugs specifically target those individuals whose tumor development is encouraged by the action of the COX-2 enzyme.

Dr. Markowitz' accompanying editorial maps out those studies which will be required to determine the potential use of aspirin in prevention of colon cancer and to determine which individuals might benefit most from taking aspirin or aspirin-like drugs (NSAIDS) such as ibuprofen and Celebrex. Finally, the editorial outlines potential
'"/>

Contact: Alicia Reale
Alicia.Reale@UHhospitals.org
216-844-3825
University Hospitals of Cleveland
23-May-2007


Page: 1 2

Related medicine news :

1. Springer and the Royal Academy of Medicine of Ireland enter into publishing partnership
2. Ireland leads Europe for anti-tobacco policies while Luxembourg comes last
3. Coronary heart disease deaths in Ireland have halved in 15 years
4. Smoking ban is protecting bar workers in Ireland
5. American Cancer Society to hold third annual Virtual Relay For Life in Second Life
6. Cancer research summaries
7. Cancer on the agenda of the Portuguese EU Council Presidency
8. Tony Hunter receives Robert. J. and Claire Pasarow Award for Cancer Research
9. OHSU Cancer Institute shows findings of immunotherapy vaccine in prostate cancer patients
10. OHSU Cancer Institute, VA researchers find way to identify which men need a second biopsy
11. OHSU Cancer Institute researcher identifies protein marker for prostate cancer survival

Post Your Comments:
(Date:2/27/2015)... 27, 2015 The report analyzes the ... the global celiac disease market. It also assesses key ... development activities, and investments. , Celiac disease is an ... the small intestine. Celiac disease often has a genetic ... people is affected by celiac disease across the globe. ...
(Date:2/27/2015)... WI (PRWEB) February 27, 2015 UAS ... Adult Cubes, at Natural Products Expo West, March 6 ... are very excited to release the hands down best ... cream taste with an extra zing of Vitamin C. ... Cubes, winner of the NutrAward 2014, Delicious Living’s Supplement ...
(Date:2/27/2015)... 27, 2015 The Willliams Companies Inc ... Lincoln County, Wyoming. The plant processes natural gas ... interstate natural gas pipeline transport. It also produces natural ... plant initially began operations in 1958, and in recent ... gas production in Wyoming. The plant currently has ...
(Date:2/27/2015)... The Connecticut Community for Addiction Recovery ... Alcohol and Drug Recovery Centers (ADRC), for its shared ... were honored with the 2014 Commissioner’s Recognition Award by ... Last year, ROES achieved the highest rate ... are recovering from alcoholism and other drug addiction. ...
(Date:2/27/2015)... 2015 First Choice Emergency Room ... today. The new facility is located 25551 E. Smoky Hill ... are pleased to be a part of the Aurora community ... care here,” said Dr. Dombro, Facility Medical Director of First ... To celebrate the opening, First Choice Emergency Room made a ...
Breaking Medicine News(10 mins):Health News:Global Celiac Disease Market Counts on Drug Launch for Growth 2Health News:Global Celiac Disease Market Counts on Drug Launch for Growth 3Health News:UAS LifeSciences to Launch UP4 Adult Cubes at Expo West 2Health News:Clean Water Systems Supplies Advanced Chlorine Disinfection Skid for Wyoming Gas Plant 2Health News:First Choice Emergency Room Opens New Facility in Aurora, Colorado 2
(Date:2/26/2015)... , Feb. 26, 2015  Unetixs ... noninvasive peripheral vascular physiologic testing solutions, today ... SSI, FR0010526814), the highly innovative medical imaging ... Doppler to bring SuperSonic Imagine,s technology to ... Unetixs SSI Aixplorer Ultrasound System combines ...
(Date:2/26/2015)... WORTH, Texas , February 26, 2015 ... Boston Scientific, Inc. (U.S) are the leaders in the ... , and Turkish neuromodulation market and is expected to lead ... in 1949, Medtronic, Inc. is the top player in the ... of implants for specific applications. Interstim and Entera Neurostimulator are ...
(Date:2/26/2015)... 2015 ANSYS (NASDAQ: ANSS ) ... diesel engines and global power leader, Cummins Inc., has ... to the ANSYS ® portfolio. This enterprise license ... of the industry,s most challenging multiphysics problems – providing ... on the market. The multi-year agreement provides ...
Breaking Medicine Technology:Unetixs Vascular Announces Partnership with SuperSonic Imagine 2Unetixs Vascular Announces Partnership with SuperSonic Imagine 3Middle East & Africa Internal Neurostimulation/Neuromodulation Market is Expected to Reach $6.1 Million by 2019, at a CAGR of 17.9% from 2014 to 2019 2Middle East & Africa Internal Neurostimulation/Neuromodulation Market is Expected to Reach $6.1 Million by 2019, at a CAGR of 17.9% from 2014 to 2019 3Middle East & Africa Internal Neurostimulation/Neuromodulation Market is Expected to Reach $6.1 Million by 2019, at a CAGR of 17.9% from 2014 to 2019 4Cummins Standardizes On ANSYS Engineering Simulation Software 2Cummins Standardizes On ANSYS Engineering Simulation Software 3
Cached News: